Maxwell Hamilton - wikipedia.orgFollowing Merck Sharp & Dohme (MSD)’s US$10bn acquisition of Verona Pharma and its potential COPD blockbuster Ohtuvayre®, GlaxoSmithKline (GSK) has secured a US$12bn deal for another PDE3/PDE4 inhibitor.
ADVERTISEMENT
Following Merck Sharp & Dohme (MSD)’s US$10bn acquisition of Verona Pharma and its potential COPD blockbuster Ohtuvayre®, GlaxoSmithKline (GSK) has secured a US$12bn deal for another PDE3/PDE4 inhibitor.